INTEGRA LIFESCIENCES HOLDINGS CORP Financial Summary

Quick Answer

INTEGRA LIFESCIENCES HOLDINGS CORP reported Total Revenue of $1.64 billion for fiscal year 2025.

INTEGRA LIFESCIENCES HOLDINGS CORP — Key Financials by Year

Metric 2025 2024 2023 2022 2021 2020
Total Revenue $1.64B
+1.5%
$1.61B
+4.5%
$1.54B
-1.0%
$1.56B
+1.0%
$1.54B
+12.4%
$1.37B
-9.6%
Revenue (ASC 606) $1.64B
+1.5%
$1.61B
+4.5%
$1.54B
-1.0%
$1.56B
+1.0%
$1.54B
+12.4%
$1.37B
-9.6%
Net Income -$516.47M
-7337.7%
-$6.94M
-110.3%
$67.74M
-62.5%
$180.55M
+6.8%
$169.07M
+26.3%
$133.89M
+166.7%
Diluted EPS -$6.74
-7388.9%
-$0.09
-110.7%
$0.84
-61.1%
$2.16
+9.1%
$1.98
+26.1%
$1.57
+170.7%
Total Assets $3.60B
-10.8%
$4.04B
+6.8%
$3.78B
-2.8%
$3.89B
+2.8%
$3.78B
+4.6%
$3.62B
+9.4%
Cash and Equivalents $235.05M
-4.6%
$246.38M
-10.9%
$276.40M
-39.5%
$456.66M
-11.1%
$513.45M
+9.2%
$470.17M
+136.4%
Stockholders Equity $1.04B
-32.5%
$1.55B
-2.7%
$1.59B
-12.0%
$1.80B
+7.1%
$1.68B
+11.2%
$1.51B
+6.9%
R&D Expense
Operating Income -$493.37M
-1836.5%
$28.41M
-74.5%
$111.53M
-53.3%
$238.92M
+21.1%
$197.23M
+30.3%
$151.37M
+61.4%

Most Recent Quarter

Metric Quarter Ending Value YoY QoQ
Total Revenue September 30, 2025 $402.06M +5.6% -3.3%
Revenue (ASC 606) September 30, 2025 $402.06M +5.6% -3.3%
Net Income September 30, 2025 -$5.40M +49.5% +98.9%
Diluted EPS September 30, 2025 -$0.07 +50.0% +98.9%
Total Assets September 30, 2025 $3.65B -10.3% -0.6%
Cash and Equivalents September 30, 2025 $232.19M +7.9% +6.5%
Stockholders Equity September 30, 2025 $1.04B -31.8% -0.1%
R&D Expense June 30, 2020 $14.93M -15.4% -28.3%
Operating Income September 30, 2025 $11.76M +244.3% +102.3%
  • INTEGRA LIFESCIENCES HOLDINGS CORP reported Total Revenue of $1.64 billion for fiscal year 2025.
  • INTEGRA LIFESCIENCES HOLDINGS CORP showed an increase of +1.5% in Total Revenue compared to the prior fiscal year.
  • INTEGRA LIFESCIENCES HOLDINGS CORP reported Revenue (ASC 606) of $1.64 billion for fiscal year 2025.
  • INTEGRA LIFESCIENCES HOLDINGS CORP showed an increase of +1.5% in Revenue (ASC 606) compared to the prior fiscal year.
  • INTEGRA LIFESCIENCES HOLDINGS CORP reported Net Income of -$516.47 million for fiscal year 2025.
  • INTEGRA LIFESCIENCES HOLDINGS CORP showed a decrease of -7337.7% in Net Income compared to the prior fiscal year.
  • INTEGRA LIFESCIENCES HOLDINGS CORP reported Diluted EPS of $6.74 per share (loss) for fiscal year 2025.
  • INTEGRA LIFESCIENCES HOLDINGS CORP showed a decrease of -7388.9% in Diluted EPS compared to the prior fiscal year.
  • INTEGRA LIFESCIENCES HOLDINGS CORP reported Total Assets of $3.60 billion for fiscal year 2025.
  • INTEGRA LIFESCIENCES HOLDINGS CORP showed a decrease of -10.8% in Total Assets compared to the prior fiscal year.
  • INTEGRA LIFESCIENCES HOLDINGS CORP reported Cash and Equivalents of $235.05 million for fiscal year 2025.
  • INTEGRA LIFESCIENCES HOLDINGS CORP showed a decrease of -4.6% in Cash and Equivalents compared to the prior fiscal year.
  • INTEGRA LIFESCIENCES HOLDINGS CORP reported Stockholders Equity of $1.04 billion for fiscal year 2025.
  • INTEGRA LIFESCIENCES HOLDINGS CORP showed a decrease of -32.5% in Stockholders Equity compared to the prior fiscal year.
  • INTEGRA LIFESCIENCES HOLDINGS CORP reported R&D Expense of $78.04 million for fiscal year 2018.
  • INTEGRA LIFESCIENCES HOLDINGS CORP showed an increase of +23.0% in R&D Expense compared to the prior fiscal year.
  • INTEGRA LIFESCIENCES HOLDINGS CORP reported Operating Income of -$493.37 million for fiscal year 2025.
  • INTEGRA LIFESCIENCES HOLDINGS CORP showed a decrease of -1836.5% in Operating Income compared to the prior fiscal year.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment